Investigational retatrutide reduced knee osteoarthritis pain and body weight versus placebo in adults with obesity

1. In patients with obesity and painful knee osteoarthritis, treatment with retatrutide at 9mg or 12mg in TRIUMPH-4 and at 4mg, 9mg, or 12mg in TRIUMPH-1-OA significantly decreased WOMAC pain scores. 2. Retatrutide at 9mg or 12mg in TRIUMPH-4 also significantly decreased percent change in body weight. Evidence Rating Level: 1 (Excellent) Study Rundown: In two phase 3 trials (TRIUMPH-4 and TRIUMPH-1-OA), once-weekly investigational retatrutide reduced WOMAC pain mean scores significantly more than placebo, on a 0-10 scale. In TRIUMPH-4, participants receiving retatrutide had mean body-weight changes of -20.0% and -23.7% at 9 mg and 12 mg, respectively, versus -4.6% with placebo. All participants had obesity and painful knee osteoarthritis (OA). The mechanism responsible for the reported pain reduction with treatment with triple GIP, GLP-1, and glucagon receptor agonist are not completely understood, but in these participants, it is theorized that the weight reduction leads to decreased loading on the knee. Serious adverse events were more common with retatrutide than with placebo, and gastrointestinal events were the most common adverse events, leading to discontinuation in 2.8 – 18.2% of retatrutide arms and 4.0 – 6.2% of placebo arms. Limitations included no WOMAC scoring within the early weeks of treatment, limited inflammatory biomarker data as they were only assessed at baseline, limited generalizability to overweight and OA populations, and no direct comparisons to other treatments such as NSAIDs, tramadol, intraarticular glucocorticoids and semaglutide. Click here to read the study in the NEJM (New England Journal of Medicine) In-Depth [randomized controlled trial]: Authors summarized two phase 3 trial results, TRIUMPH-4 and TRIUMPH-1-OA). Both trials were international, double blind, randomized, controlled trials with adults aged 18 or older who had chronic knee pain and BMI ≥ 27. Chronic knee pain was defined as chronic pain over a period of > 12 weeks before screening and in the presence of pain on > 15 days in the month before screening. Inclusion criteria also included radiographic evidence of knee osteoarthritis (OA), WOMAC pain (version 3.1) score of at least 4 but no more than 9, and at least one previous participant-reported unsuccessful dietary effort to lose body weight. Exclusion criteria included weight change of more than 5 kg within 90 days before screening, and any conditions that could confound assessments of obesity or OA knee pain, and diabetes. Enrollment of females were capped at 70% to ensure representation of male participants. Participants were randomized into receiving once-weekly subcutaneous retatrutide vs placebo. Stratification was done by WOMAC pain scores at baseline (≥7 severe pain vs <7 moderate pain), if they were prediabetic, and by sex. TRIUMPH-4 included 445 participants at 49 centers who had a BMI of at least 27 Randomization was 1:1:1 of either 9mg or 12mg retatrutide or placebo, once weekly for 68 weeks. TRIUMP-1-OA included 574 participants at 66 centers, who had a BMI of at least 30, or at least 27 with one or more complications of obesity. Randomization was 1:1:1:1 of either 4mg, 9mg, or 12mg retatrutide or placebo, once weekly for 80 weeks. In both trials, a dose of 2mg was initiated, and titrated up to their target dose every 4 weeks. Participants could also have doses reduced if there was excessive weight loss, BMI ≤ 22, inadequate oral intake, and for gastrointestinal adverse events. TRIUMPH-4’s primary end points were change in WOMAC pain and percent change in body weight after 68 weeks. Secondary end points included WOMAC physical function score changes at 36 and 68 weeks, and WOMAC pain score changes at 36 weeks. TRIUMPH-1-OA’s primary end points were change in WOMAC pain after 80 weeks for 9mg and 12mg arms. Secondary end points included change in WOMAC pain after 80 weeks in the 4mg arm, percent body weight change after 80 weeks, the change in WOMAC physical function scores at 36-, 68-, and 80-weeks, and the change in WOMAC pain scores at 36 and 68 weeks. Both trials included a secondary end point of body weight percent change at end of trial for those with a BMI of at least 35. Prespecified key secondary endpoints were controlled for Type I error. TRIUMPH-4 randomized 148 to 9mg, 148 to 12mg, and 149 to placebo, and 71.9% completed their assigned course and completed the trial. TRIUMP-1-OA randomized 143 to 4mg, 143 to 9mg, 144 to 12mg, and 144 to placebo, and 75.4% completed their assigned course and completed the trial. At baseline, mean age was 55-56 years, mean BMI was 40.5 (with about 83% with BMI ≥35), mean WOMAC pain was 6.0, and almost all participants had Kellgren-Lawrence grades of 2 or 3. For knee OA outcomes, the investigators used a hybrid-treatment estimand that applied a hypothetical strategy to intercurrent events associated with treatment failure and a treatment-policy strategy to other intercurrent events. An intention-to-treat (ITT) estimand was also reported, which included outcomes regardless of treatment discontinuation or other intercurrent events. ITT in TRIUMPH-4, the differences from placebo after 68 weeks for WOMAC pain scores were -1.70 for 9mg (95% CI -2.19 to -1.22) and -1.38 for 12mg (95% CI, -1.91 to -0.85), and p<0.001 for all comparisons. The hybrid-treatment estimand were -3.96 for 9mg and -3.74 for 12mg, vs -2.12 for placebo (difference vs placebo, -1.83 [95% CI, -2.37 to -1.30] and -1.61 [95% CI, -2.16 to -1.07]). Mean percent changes in body weight were -20.0% for 9mg and -23.7% for 12mg versus -4.6% placebo (difference vs placebo, -15.4 percentage points [95% CI, -18.7 to -12.1] and -19.2 percentage points [95% CI, -22.4 to -15.9]) with p<0.001 for both comparisons. The differences from placebo after 68 weeks for WOMAC physical function scores were -1.83 for 9mg (95% CI, -2.40 to -1.27) and -1.77 for 12mg (95% CI, -2.34 to -1.20) with p<0.001 for both comparisons. ITT in TRIUMPH-1-OA, the differences from placebo after 80 weeks for WOMAC pain scores were -0.96 (95% CI, -1.61 to -0.30), -1.41 (95% CI, -2.07 to -0.75), and -1.64 (95%, -2.26 to -1.02) with p≤0.005 for all comparisons. The hybrid-treatment estimand mean changes were -3.22 for 4mg, -3.48 for 9mg, and -3.64 for 12mg, vs -1.87 with placebo (difference vs placebo, -1.35 [95% CI, -1.92 to -0.78], -1.61 [95% CI, -2.20 to -1.02], and -1.77 [95% CI, -2.34 to -1.20]. After 80 weeks the difference from placebo in percent change in body weight was -13.2 percentage points for 4mg (95% CI, -16.1 to -10.4), -18.6 for 9mg (95% CI, -21.4 to -15.8), and -20.6 for 12mg (95% CI, -23.6 to -17.5), with p<0.001 for all comparisons. After 80 weeks the difference from placebo for WOMAC physical function scores were -1.68 for 4mg (95% CI, -2.23 to -1.12), -1.89 for 9mg (95% CI, -2.49 to -1.29), and -1.95 for 12mg (95% CI, -2.52 to -1.38) with p< 0.001 for all comparisons. In TRIUMPH-4, treatment with retatrutide at 9mg or 12mg significantly reduced WOMAC pain and body weight versus placebo; in TRIUMPH-1-OA, treatment with retatrutide at 4mg, 9mg, or 12mg significantly reduced WOMAC pain versus placebo in patients with knee OA and obesity. Citation: Schnitzer TJ, Hunter DJ, Conaghan PG, Sharma AM, Pedersen SD, Chen K, et al. Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesity . N Engl J Med. 2026 Nov 8. doi: 10.1056/nejmoa2610676. Epub ahead of print. PMID: 43001755. © 2026 2 Minute Medicine, Inc. All rights reserved. No part of this article may be reproduced, distributed or transmitted in any form or by any means without the prior written permission of 2 Minute Medicine, Inc. To license this content , contact 2 Minute Medicine, Inc. This article is for informational and educational purposes only; it is not medical advice and does not replace the judgment of a qualified healthcare professional. Image: © 2 Minute Medicine